CYFRA 21-1 Serum Levels in Women with Ovarian Cancer
Author Information
Author(s): C Tempfer, L Hefter, H Heinzl, A Loeschl, G Gitsch, H Rumpold, C Kainzl
Primary Institution: University of Vienna Medical School
Hypothesis
Can CYFRA 21-1 serve as a useful marker for ovarian cancer screening, prediction, and prognosis?
Conclusion
CYFRA 21-1 is not suitable for screening or differential diagnosis of adnexal masses but may be a prognostic factor in ovarian cancer.
Supporting Evidence
- CYFRA 21-1 had a sensitivity of 41% and a specificity of 95% in ovarian cancer patients.
- Elevated CYFRA 21-1 serum levels before therapy were associated with poor overall and disease-free survival.
- CYFRA 21-1 did not provide additional diagnostic information compared to CA 125.
Takeaway
This study looked at a blood test called CYFRA 21-1 to see if it can help find or predict ovarian cancer, but it turns out it’s not very good for that.
Methodology
Retrospective study analyzing serum levels of CYFRA 21-1 in patients with ovarian cancer and benign conditions.
Potential Biases
Potential bias in patient selection and retrospective nature of the study.
Limitations
The study is retrospective and may not account for all variables affecting serum levels.
Participant Demographics
Median age of ovarian cancer patients was 57.9 years; included women with benign conditions and healthy controls.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website